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Acute Flaccid Myelitis: Patient Summary Form 
FOR LOCAL USE ONLY 
Name of person completing form: ______________________________________________   State assigned patient ID: _______________________ 
Affiliation__________________________________ Phone:  ____________________________Email:  _____________________________________ 
Name of physician who can provide additional clinical/lab information, if needed ______________________________________________________ 
Affiliation_____________________________________ Phone:  ___________________________ Email: ___________________________________ 
Name of main hospital that provided patient’s care: ___________________________________    State:  _____  County: ______________________ 
-------------------------------------------------------------DETACH and transmit only lower portion to limbweakness@cdc.gov if sending to CDC------------------------------------------------------------- 
 Acute Flaccid Myelitis: Patient Summary Form
Form to be completed by, or in conjunction with, a physician who provided care to the patient during the neurological
illness. Once completed, submit to Health Department (HD). HD can also facilitate specimen testing.   
1. Today’s date__ __/__ __/__ __ __ __  (mm/dd/yyyy) 2. State assigned patient ID: ________________________________________ 
3. Sex:   M     F    4. Date of birth __ __/ __ __/ __ __ __ __ Residence: 5. State_______    6. County_____________________________
7. Race:   American Indian or Alaska Native      Asian        Black or African American   8. Ethnicity:   Hispanic or Latino
Native Hawaiian or Other Pacific Islander      White       (check all that apply)                                         Not Hispanic or Latino 
9. Date of onset of limb weakness   __ __/__ __/__ __ __ __  (mm/dd/yyyy) 10. Was patient admitted to a hospital?   yes     no      unknown
11.Date of admission to first hospital__ __/__ __/__ __ __ __  12.Date of discharge from last hospital__ __/__ __/__ __ __ __(or  still hospitalized 
at time of form submission)   
13. Did the patient die from this illness?  yes   no    unknown        14. If yes, date of death__ __/__ __/__ __ __
Other patient information: 
SIGNS/SYMPTOMS/CONDITION: 
Right Arm Left Arm Right Leg Left Leg 
15. Since neurologic illness onset, which limbs have been acutely weak?
[indicate yes(y), no (n), unknown (u) for each limb] Y       N       U Y        N       U Y        N       U Y        N       U 
16. Date of neurologic exam (recorded at most severe weakness to point of
completing this form)  (mm/dd/yyyy) 
__  __ /__  __/__ __ __ __ 
17. At the time of most severe weakness, reflexes in the most affected
limb(s):  Areflexic/hyporeflexic (0-1)   Normal (2)   Hyperreflexic (3-4+) 
At ANY time during the illness, was there: 
18. Any sensory loss/numbness in the affected limb(s), at any time during 
the illness? (paresthesias should not be considered here) 
Y       N       U 




20. Sensory level on the torso (i.e., reduced sensation below a certain level of the torso)?
21. Did patient have any of the cranial nerve features below? (If yes, check all that apply):
Diplopia/double vision (If yes, circle the cranial nerve involved if known:  3  /  4  /  6 )  
Loss of sensation in face      Facial droop          Hearing loss         Dysphagia     Dysarthria   
22. Bowel or bladder incontinence?
23. Change in mental status (e.g., confused, disoriented, encephalopathic)?
24. Seizure(s)?
25. Receipt of positive pressure ventilation, including invasive or non-invasive ventilation and including BiPAP or
CPAP? 
In the 4-weeks BEFORE onset of limb weakness, did patient: Yes No Unk/NR 
26. Have a respiratory illness? 27. If yes, onset date    __ __/__ __/__ __ __ __
28. Have a gastrointestinal illness (e.g., diarrhea or vomiting)? 29. If yes, onset date  __ __/__ __/ __ __ __ __
30. Have a new onset rash? 31. If yes, onset date    __ __/__ __/__ __ __ __
32. Have a fever, measured by parent or provider and ≥ 38.0°C/100.4°F? 33. If yes, onset date    __ __/__ __/__ __ __ __
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Neuroradiographic findings: 
MRI of spinal cord        44. Was MRI of spinal cord performed?   yes      no       unknown      
45. If yes, how many documented spinal MRIs were performed? ________
If yes to Q44, complete Q46-Q71 based on most abnormal spine MRI            46. Date of most abnormal spine MRI __ __/__ __/__ __ __ __
47. Levels imaged:  cervical     thoracic    lumbosacral    unknown    
34. Receive any immunosuppressing agent(s) (BEFORE WEAKNESS ONSET)?
35. If yes: Date of first administration:
__ __/ __ __ / __ __ __ __  
Name of medication: _____________________ 
Mode of administration: IM     IV    Oral 
Dosage / duration / overall amount 
administered: 
_______________________________________ 
36. Travel outside the US? 37. If yes, list country:
38. At onset of limb weakness, does patient have any underlying illnesses? 39. If yes, list:
40. On the day of onset of limb weakness, did patient have a fever? (see definition for fever above in 32.) 
Polio vaccination history: 
41. How many doses of inactivated polio vaccine (IPV) are documented to have been received by
the patient before the onset of weakness? _______doses       unknown 
42. How many doses of oral polio vaccine (OPV) are documented to have been received by the 
patient before the onset of weakness? _______doses       unknown 
43. If you do not have documentation of the type of polio vaccine received what is total number of
documented polio vaccine doses received before onset of weakness? _______doses      unknown 
48. Location of lesions:
cervical cord    thoracic cord 
conus                cauda equina 
unknown 
Levels of cord affected (if applicable): 
49. Cervical: _________ 50. Thoracic: _________
For cervical and thoracic 
cord lesions 
51. What areas of spinal cord were
affected?
predominantly gray matter               predominantly white matter   
both equally affected         unknown 
52. Was there cord edema?  yes         no          unknown      
53. Gadolinium (GAD) used:  yes         no          unknown          (If NO, skip to question 59) 
For cervical, thoracic cord 
or conus lesions 
54. Did any gray matter lesions 
enhance with GAD? 
 yes          no          unknown         
55. Did any white matter lesions 
enhance with GAD? 
 yes          no          unknown     
56. Did any cervical / thoracic nerve
roots enhance with GAD? 
 yes          no          unknown     
For cauda equina lesions 57. Did the ventral nerve roots 
enhance with GAD?
 yes          no        unknown     
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MRI of brain 
59. Was brain/brainstem/cerebellum MRI performed?     yes    no     unknown   (If NO, skip to Q72)    60. Date of study __ __/__ __/__ __ __ __
72. Was an EMG done?          yes          no          unknown      If yes, date  __ __/__ __/__ __ __ __    (mm/dd/yyyy)  
73. If yes, was there evidence of acute motor neuropathy, motor neuronopathy, motor nerve or anterior horn cell involvement?  yes   no   unk
CSF examination: 74. Was a lumbar puncture performed?    yes        no       unknown  
If yes, complete 74 (a,b) (If more than 2 CSF examinations, list the first 2 performed)  
58. Did the dorsal nerve roots 
enhance with GAD?
 yes          no        unknown     
61. Any supratentorial (i.e, lobe, cortical, subcortical, basal
ganglia, or thalamic) lesions 
 yes      no        unknown     
62.If yes, indicate location(s)
cortex     basal ganglia     thalamus        
 subcortex              unknown 
Other (specify): ____________________        
63. Any brainstem lesions?  yes      no        unknown     
64. If yes, indicate location:
midbrain        pons           medulla             
unknown 
65. Any cranial nerve lesions?  yes      no        unknown     
66. If yes, indicate which
CN(s):
CN_____ unilateral   bilateral 
CN_____ unilateral   bilateral 
CN_____ unilateral   bilateral 
CN_____ unilateral   bilateral 
67. Any lesions affecting the cerebellum?  yes      no        unknown     
68. Gadolinium (GAD) used:    yes       no       unknown          (If NO, skip to question 72) 
69. Did any supratentorial lesions enhance with GAD?  yes      no       unknown     
70. Did any brainstem lesions enhance with GAD?  yes      no       unknown     
71. Did any cranial nerve lesions enhance with GAD?  yes      no       unknown     
Date of lumbar 





74a. CSF from LP1 
74b. CSF from LP2 
75. Was CSF tested?       yes   no   unknown      Specimen Collection Date   __ __ / __ __/  __ __ __ __ 
If ‘yes’, was specimen tested for the following:
Enterovirus 
 yes   no   unknown 
Test Type Test Result Typed (if positive)? Type 
PCR  Positive   Negative   Pending  yes       no       not done _______ 
West Nile Virus 
 yes    no   unknown 
PCR  Positive   Negative   Pending 
West Nile Virus 
 yes    no   unknown IgM 
 Positive   Negative   
 Indeterminate   Pending    
Unknown 
Herpes simplex virus 
 yes   no   unknown PCR  Positive   Negative   Pending 
Cytomegalovirus 
 yes  no   unknown 
PCR  Positive   Negative   Pending 
Varicella zoster virus 
 yes    no   unknown 
PCR  Positive   Negative   Pending 
Was other pathogen 
identified: 
 yes   no   unknown 
If positive for other 
pathogen,  specify test 
type: 
_____________ 
List other pathogen(s) identified: 
Pathogen testing performed: 
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79. Was/Is a specific etiology considered to be the most likely cause for the patient’s neurological illness?      yes       no       unknown
80. If yes, please list etiology and reason(s) considered most likely cause ____________________________________________________________
_______________________________________________________________________________________________________________________ 
81. If patient is a confirmed or probable case, will specimens be sent to CDC for testing?   yes       no         unknown 
82. If yes, types of specimens that will be sent to CDC for testing:
  CSF     Nasal wash/aspirate    BAL spec     Tracheal aspirate        NP/OP swab      Stool      Serum      Other, list __________________      
76. Was a RESPIRATORY TRACT specimen tested?         yes   no   unknown          Specimen Collection Date     __ __ / __ __/  __ __ __ __
Type of specimen:  nasopharyngeal swab      nasal wash/aspirate      oropharyngeal swab      other, specify: ________________________
If ‘yes’, was specimen tested for the following:
Enterovirus/rhinovirus
 yes    no   unknown 
Test Type Test Result Typed (if positive)? Type 
PCR   Positive   Negative   Pending  yes       no        not done _______ 
Adenovirus 
 yes    no   unknown     
PCR  Positive   Negative   Pending  yes      no         not done _______ 
Influenza virus 
 yes    no   unknown PCR  Positive   Negative   Pending  yes      no         not done _______ 
Was other pathogen 
identified: 
 yes   no   unknown 
If positive for other 
pathogen,  specify test 
type: 
_____________ 
List other pathogen(s) identified: 
77. Was a STOOL specimen tested?       yes   no   unknown Specimen Collection Date      __ __ / __ __/  __ __ __ __ 
If ‘yes’, was specimen tested for the following:
Non-polio Enterovirus 
 yes    no   unknown     
Test Type Test Result Typed (if positive)? Type 
PCR  Positive      Negative      Pending  yes     no      not done _______ 
Poliovirus 
 yes    no   unknown 
 PCR  Positive      Negative      Pending 
Poliovirus 
 yes    no   unknown 
Culture  Positive      Negative      Pending 
Was other pathogen 
identified: 
 yes   no   unknown 
If positive for other 
pathogen,  specify test 
type: 
_____________ 
List other pathogen(s) identified: 
78. Was SERUM tested?        yes   no   unknown Specimen Collection Date  __ __ / __ __/  __ __ __ __ 
If ‘yes’, was specimen tested for the following:
West Nile Virus 
 yes    no   unknown 
Test Type Test Result Typed (if positive)? Type 
PCR  Positive      Negative       Pending 
West Nile Virus 
 yes    no   unknown     
IgM 
 Positive   Negative   
Indeterminate    Pending      
Unknown 
Was other pathogen 
identified: 
 yes   no   unknown 
If positive for other 
pathogen,  specify test 
type: 
_____________ 
List other pathogen(s) identified: 
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Acute Flaccid Myelitis case definition 
(http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/2015PS/2015PSFinal/15-ID-01.pdf) 
Criteria 
An illness with onset of acute focal limb weakness AND 
● a magnetic resonance image (MRI) showing spinal cord lesion largely restricted to gray matter and spanning one or more
spinal segments, OR
● cerebrospinal fluid (CSF) with pleocytosis (white blood cell count >5 cells/mm3)
Case Classification 
Confirmed: 
● An illness with onset of acute focal limb weakness AND
● MRI showing spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments
Probable: 
● An illness with onset of acute focal limb weakness AND
● CSF showing pleocytosis (white blood cell count >5 cells/mm3).
